Interest in CBD for quitting smoking has grown because early studies found signals worth investigating. Yet current evidence does not establish cannabidiol as a proven smoking-cessation treatment. U.S. smokers have better-supported options, including counseling, nicotine replacement therapy, varenicline, and bupropion.
Direct answer: Early human research suggests cannabidiol might affect cigarette use or responses to smoking cues. The studies were small and did not prove that it helps people quit long-term. The FDA has not approved cannabidiol for smoking cessation, so it should not replace established treatments.
| Key question | Current U.S.-focused answer |
|---|---|
| Is cannabidiol FDA-approved for quitting cigarettes? | No |
| Does research suggest possible effects? | Yes, but human evidence remains limited. |
| Does it clearly reduce withdrawal or cravings? | Not established |
| What treatments have stronger evidence? | Counseling, NRT, varenicline, and bupropion |
| Can cannabidiol cause side effects? | Yes. |
| Can it interact with medications? | Yes. |
| Should smokers rely on it alone? | Current evidence does not support that approach |
Key Takeaways
- Human research on cannabidiol and cigarette smoking remains small and preliminary.
- A 2013 pilot study reported fewer cigarettes during one week of cannabidiol inhaler use.
- A later study found changes in responses to smoking cues but not cravings or withdrawal.
- The FDA has not approved over-the-counter cannabidiol products to treat nicotine dependence.
- Cannabidiol can cause side effects and may interact with medications.
- Counseling and FDA-approved cessation medicines have much stronger evidence.
- U.S. smokers can call 1-800-QUIT-NOW for free cessation support.
Can CBD for Quitting Smoking Really Help?
Researchers have found a few signals suggesting cannabidiol deserves further study for tobacco dependence. Those signals are interesting, but they are not the same as proof. No large body of clinical evidence currently shows that retail cannabidiol products reliably help smokers become abstinent.
One frequently cited study was published in Addictive Behaviors in 2013. Researchers randomly assigned only 24 smokers to a cannabidiol inhaler or placebo for one week. Participants using cannabidiol reduced cigarette consumption by about 40% during that short treatment period. That finding has important limits for anyone deciding what to do today.
The trial was tiny, lasted only one week, and measured cigarette consumption rather than sustained quitting. Results from such a pilot study need confirmation in larger and longer clinical trials.
What Later Research Found
A 2018 randomized crossover study looked at 30 cigarette-dependent adults after overnight abstinence. Participants received either an 800-milligram oral cannabidiol dose or placebo during laboratory sessions. Cannabidiol reduced attention toward cigarette cues and lowered how pleasant participants rated cigarette images.
The study did not find lower cigarette craving or withdrawal after cannabidiol treatment. That distinction matters because cravings and withdrawal often contribute to relapse. The researchers described the findings as evidence supporting further investigation, not established cessation treatment.
Another analysis from the same research program examined memory and impulsivity during nicotine abstinence. It did not show meaningful improvements across several cognitive outcomes. Together, these studies show why early laboratory signals should not be treated as clinical proof.
Research is continuing in the United States. A UCLA-associated clinical trial is evaluating cannabidiol for reducing cigarette use over a longer period. The existence of an ongoing trial also reflects how many important questions remain unanswered.
Why the Evidence Is Still Too Limited for Firm Claims
Smoking cessation requires more than reducing cigarette consumption for several days. Researchers usually need sustained abstinence outcomes and enough participants to identify meaningful benefits. They must also compare treatment effects against placebo and established therapies.
Existing cannabidiol studies have involved small groups under controlled research conditions. The doses and formulations studied may differ substantially from ordinary retail oils, gummies, or other products. You cannot assume a store product will reproduce results from a clinical research formulation.
This gap is especially important for websites discussing wellness products. Saying research is promising is different from saying a product treats nicotine addiction. The FDA has previously challenged companies for making unsupported cannabidiol smoking-cessation claims.
What Treatments Work Better for Quitting Smoking?
The CDC identifies seven FDA-approved medicines for adults who want to stop smoking cigarettes. Five are nicotine replacement options, including patches, gum, lozenges, nasal spray, and an oral inhaler. The other approved medicines are varenicline and sustained-release bupropion.
Counseling can also help smokers plan for cravings, stress, routines, and difficult situations. Combining counseling with medication provides a stronger approach than relying on willpower alone. The CDC recommends options including individual counseling, quitlines, text programs, and online support.
For some adults, combining a nicotine patch with short-acting gum or lozenges can improve results. Varenicline is another well-supported option that can reduce urges to smoke. A clinician or pharmacist can help you compare choices based on your health and medications.
| Approach | Evidence for smoking cessation | Main role |
|---|---|---|
| Counseling | Strong | Builds coping strategies and a quit plan |
| Nicotine replacement therapy | Strong | Reduces nicotine withdrawal |
| Varenicline | Strong | Reduces urges and smoking reinforcement |
| Bupropion SR | Strong | Helps reduce withdrawal and cravings |
| Cannabidiol | Preliminary | Still under investigation |
Safety Matters Before Trying Cannabidiol
The FDA warns that cannabidiol can cause liver injury and affect how other medicines work. Reported effects can also include drowsiness, digestive symptoms, appetite changes, irritability, and agitation. Using it with alcohol or sedating medicines may increase drowsiness. Those concerns become more important when someone already uses prescription medicines for smoking cessation or another condition.
A healthcare professional can check for interactions before combining substances. The FDA recommends discussing consumer cannabidiol use with a healthcare provider. Pregnant or breastfeeding people should take extra care. The FDA advises against using cannabis products, including cannabidiol, during pregnancy or breastfeeding. Questions remain about infant exposure, reproductive effects, contamination, and other safety concerns.
Retail Product Quality Creates Another Problem
A clinical study tells researchers exactly what substance and dose participants receive. Retail cannabinoid products do not always offer the same certainty. Labels, THC content, contaminants, and manufacturing practices can vary between products. If you are researching consumer products, Nuturahey’s U.S. CBD store safety guide explains how to review labels and laboratory reports.
Those checks can help assess product quality, but they cannot prove smoking cessation effectiveness. A certificate of analysis measures product contents rather than whether a treatment works. THC exposure may create another concern for people subject to workplace testing. Nuturahey’s guide to CBD oil and drug testing explains why trace THC can matter. The site’s CBD clearance guide also covers factors affecting how long cannabinoids may remain in the body.
A Better Way to Build a Quit Plan

Start by choosing a realistic quit date and identifying situations linked with cigarettes. Common triggers include driving, alcohol, stress, work breaks, coffee, and social routines. Planning replacements ahead of time makes those moments easier to manage. Next, consider an evidence-based medication rather than waiting for cravings to become overwhelming.
Over-the-counter nicotine patches, gum, and lozenges are accessible choices for many adults. Prescription options can be discussed with a clinician when appropriate. Add behavioral support instead of treating medication as the entire plan. Free U.S. quitline coaching is available through 1-800-QUIT-NOW. Counseling plus medication generally gives smokers the strongest evidence-based chance of stopping successfully.
Finally, expect the process to require adjustment. Nicotine dependence is a relapsing condition, and another attempt can succeed after an earlier setback. Changing medication, support, routines, or trigger-management strategies may improve the next attempt.
Where Cannabidiol Might Fit in Future Research
The most responsible interpretation is that cannabidiol remains an experimental possibility for tobacco dependence. Early research provides reasons to investigate effects on cigarette consumption and smoking-related cues. It does not yet provide enough evidence for routine cessation recommendations.
Larger trials need to measure sustained abstinence rather than short-term cigarette reductions alone. Researchers also need better information about dosing, safety, medication interactions, and which smokers might benefit. Results from current studies could eventually clarify whether cannabidiol has a useful clinical role.
Until those answers exist, smokers should avoid replacing proven cessation care with an unapproved option. This is especially important for people with medical conditions or those taking prescription medicines. A quit plan can incorporate personal preferences while still prioritizing treatments supported by stronger evidence.
Frequently Asked Questions
Does CBD for quitting smoking stop nicotine cravings?
Current human evidence does not establish that it stops nicotine cravings. A 2018 controlled study found no significant reduction in craving or withdrawal compared with placebo. Researchers did observe changes in responses to cigarette-related cues.
Is cannabidiol approved by the FDA for smoking cessation?
No, the FDA has not approved cannabidiol as a smoking-cessation medicine. The agency has approved one prescription cannabidiol drug for specific seizure disorders. That approval does not establish effectiveness for nicotine dependence.
Can cannabidiol replace nicotine patches or gum?
Current evidence does not support replacing established nicotine-replacement medicines with cannabidiol. Patches, gum, lozenges, inhalers, and nasal sprays have specific smoking-cessation evidence. They are included among established U.S. cessation treatments.
Is vaping cannabidiol a good way to stop cigarettes?
There is not enough evidence to recommend that approach as a smoking-cessation treatment. Inhaling another product also introduces questions about ingredients and respiratory exposure. Proven cessation methods provide a better-supported starting point.
What is the best first step for someone ready to quit?
Choose a quit plan that combines practical support with an evidence-based treatment when appropriate. You can discuss medication with a clinician or pharmacist and call 1-800-QUIT-NOW for free coaching. Using counseling and medication together can improve your chance of success.
The Bottom Line
Cannabidiol has produced interesting early findings, but the research is not strong enough to call it a proven quitting aid. Small studies cannot establish the benefits, dose, safety, or long-term effectiveness needed for routine treatment. Current U.S. guidance favors counseling and approved cessation medicines.
If you are considering cannabidiol while trying to quit, discuss that choice with a healthcare professional first. Ask about interactions with medications and avoid abandoning treatments that already have strong evidence. Your goal should be sustained tobacco abstinence, not replacing one uncertain strategy with another.





